Cover Image
市場調查報告書

過敏性結膜炎 : 開發平台分析

Allergic Conjunctivitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192452
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
過敏性結膜炎 : 開發平台分析 Allergic Conjunctivitis - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 71 Pages
簡介

過敏性結膜炎,是覆蓋眼皮背面及結膜的組織的透明層,花粉、皮屑、霉、及其他過敏原因物質造成腫脹或發炎時發病。症狀中,包含極癢,眼瞼浮腫,覆蓋結膜的透明細胞層的血管擴張,及眼分泌物粘稠。使用抗組織胺藥物或抗發炎藥療法治療。

本報告以全球過敏性結膜炎治療藥的開發中產品為主題,提供目前開發平台狀況和最新趨勢、後期階段及中止的計劃的資訊、主要企業及開發中產品的檢討等,為您概述為以下內容。

簡介

  • 調查範圍

過敏性結膜炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

過敏性結膜炎:企業開發中的治療藥

過敏性結膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

過敏性結膜炎:企業開發中的產品

過敏性結膜炎治療藥的開發企業

  • Accolade Pharma LLC
  • Akari Therapeutics, Plc
  • Aldeyra Therapeutics, Inc.
  • Allergan Plc
  • Eleven Biotherapeutics Inc.
  • Griffin Discoveries BV
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • Ohr Pharmaceutical Inc.
  • Oxagen Limited
  • Sylentis S.A.
  • Xencor, Inc.

過敏性結膜炎:治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AGN-229666
  • AL-53817
  • cetirizine hydrochloride
  • dexamethasone acetate SR
  • 過敏性結膜炎治療藥
  • GD-134
  • GD-136
  • isunakinra
  • KBP-7306
  • NS-2
  • OC-2417
  • OPX-1
  • 眼科及氣喘用組織胺H1/H4受體拮抗小分子
  • SYL-116011
  • XmAb-7195
  • Zafi-2

過敏性結膜炎:最近的開發平台趨勢

過敏性結膜炎:暫停中的計劃

過敏性結膜炎:中止計劃

過敏性結膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8577IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1, 8 and 1 respectively for Allergic Conjunctivitis.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Conjunctivitis - Overview
  • Allergic Conjunctivitis - Therapeutics under Development by Companies
  • Allergic Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Allergic Conjunctivitis - Products under Development by Companies
  • Allergic Conjunctivitis - Companies Involved in Therapeutics Development
    • Accolade Pharmaceuticals, LLC
    • Aldeyra Therapeutics Inc
    • Allergan Plc
    • Clevexel Pharma SA
    • Griffin Discoveries BV
    • NicOx S.A.
    • Ocular Therapeutix, Inc.
    • Ohr Pharmaceutical Inc.
    • Portola Pharmaceuticals, Inc.
    • Re-Pharm Limited
    • Sylentis S.A.U.
    • Xencor, Inc.
  • Allergic Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGN-229666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetirizine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Allergic Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-136 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-2761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-0217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-116011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-7195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zafi-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Allergic Conjunctivitis - Dormant Projects
  • Allergic Conjunctivitis - Discontinued Products
  • Allergic Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
      • Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis
      • Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis
      • Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis
      • Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
      • Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis
      • Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
      • Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial
      • Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
      • Nov 24, 2014: Ora-CAC Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix's OTX-DP in Allergic Conjunctivitis
      • Nov 12, 2014: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
  • Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016
  • Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2016
  • Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, H2 2016
  • Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016
  • Allergic Conjunctivitis - Pipeline by NicOx S.A., H2 2016
  • Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Allergic Conjunctivitis - Pipeline by Re-Pharm Limited, H2 2016
  • Allergic Conjunctivitis - Pipeline by Sylentis S.A.U., H2 2016
  • Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Allergic Conjunctivitis - Dormant Projects, H2 2016
  • Allergic Conjunctivitis - Dormant Projects (Contd..1), H2 2016
  • Allergic Conjunctivitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Allergic Conjunctivitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top